CJC-1295 + Ipamorelin GH-Pulse Protocol
Lean mass support, recovery, and sleep quality via GH-pulse amplification
Overview
CJC-1295 (a GHRH analog) and Ipamorelin (a selective GH secretagogue/ghrelin mimetic) are near-universally stacked together, since they act on different receptors to amplify the same GH pulse. Community protocols center dosing around bedtime, since GH release naturally peaks during early sleep.
Dosing schedule
Informational only — not medical advice.
| Phase | Amount | Frequency | Timing | Route |
|---|---|---|---|---|
| Standard | 100 mcg CJC-1295 / 200–300 mcg Ipamorelin | 5–7x/week | Immediately before bed, fasted (2–3h post-meal) | subcutaneous injection |
Administration
Both peptides are typically reconstituted separately with bacteriostatic water and combined in the same syringe immediately before injection. Fasted state (no food 2–3h prior) is commonly cited as improving the GH response.
Cycle length
12 weeks on, 4 weeks off. Longer on-cycles are common for this blend versus injury-focused peptides, since the goal is a sustained secretagogue effect.
Precautions
- Can increase water retention and mild lethargy/flushing shortly after injection in some users.
- Growth-hormone-axis stimulation is a meaningful physiological effect — avoid if you have any active malignancy (theoretical growth-signaling concern) without medical guidance.
- Not appropriate for anyone with uncontrolled diabetes without medical supervision (GH secretagogues can affect insulin sensitivity).